KR102721222B1 - 제대혈로부터 cik nkt 세포의 생성 - Google Patents

제대혈로부터 cik nkt 세포의 생성 Download PDF

Info

Publication number
KR102721222B1
KR102721222B1 KR1020237030695A KR20237030695A KR102721222B1 KR 102721222 B1 KR102721222 B1 KR 102721222B1 KR 1020237030695 A KR1020237030695 A KR 1020237030695A KR 20237030695 A KR20237030695 A KR 20237030695A KR 102721222 B1 KR102721222 B1 KR 102721222B1
Authority
KR
South Korea
Prior art keywords
cells
cik nkt
cik
cell population
cer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237030695A
Other languages
English (en)
Korean (ko)
Other versions
KR20230133942A (ko
Inventor
로히트 두갈
란지트 신하
Original Assignee
이뮤너티바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤너티바이오, 인크. filed Critical 이뮤너티바이오, 인크.
Priority to KR1020247034929A priority Critical patent/KR102778139B1/ko
Publication of KR20230133942A publication Critical patent/KR20230133942A/ko
Application granted granted Critical
Publication of KR102721222B1 publication Critical patent/KR102721222B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237030695A 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성 Active KR102721222B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247034929A KR102778139B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862696131P 2018-07-10 2018-07-10
US62/696,131 2018-07-10
KR1020217003409A KR102577954B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성
PCT/US2019/040145 WO2020014029A1 (en) 2018-07-10 2019-07-01 Generating cik nkt cells from cord blood

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003409A Division KR102577954B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247034929A Division KR102778139B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Publications (2)

Publication Number Publication Date
KR20230133942A KR20230133942A (ko) 2023-09-19
KR102721222B1 true KR102721222B1 (ko) 2024-10-24

Family

ID=67551410

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247034929A Active KR102778139B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성
KR1020237030695A Active KR102721222B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성
KR1020217003409A Active KR102577954B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020247034929A Active KR102778139B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217003409A Active KR102577954B1 (ko) 2018-07-10 2019-07-01 제대혈로부터 cik nkt 세포의 생성

Country Status (9)

Country Link
US (2) US11931382B2 (enExample)
EP (1) EP3820994A1 (enExample)
JP (3) JP7190022B2 (enExample)
KR (3) KR102778139B1 (enExample)
CN (2) CN119372142A (enExample)
AU (2) AU2019300782B2 (enExample)
CA (1) CA3105601C (enExample)
IL (2) IL279924B2 (enExample)
WO (1) WO2020014029A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174529A1 (en) * 2020-03-04 2021-09-10 Bioeclipse Therapeutics, Inc. Methods of manufacturing activated immune cells
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
CN111690607B (zh) * 2020-06-19 2022-02-18 珠海贝索细胞科学技术有限公司 一种高效杀伤细胞体外培养试剂盒及培养方法
CN112251407A (zh) * 2020-11-03 2021-01-22 广州康琪莱精准医疗科技有限公司 一种脐带血cik细胞的扩增培养方法
CN114807044B (zh) * 2021-04-30 2023-09-08 四川大学华西医院 一种具有高nkt细胞比例的car-cik细胞制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170029777A1 (en) 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
BR9813981A (pt) 1997-11-06 2000-09-26 Roche Diagnostics Gmbh Antìgenos de tumor especìficos, métodos para a sua produção e seu uso imunização de diagnóstico
EP1117691A1 (en) 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Methods for producing human tumor antigen specific antibodies
US7098008B2 (en) 2000-04-25 2006-08-29 Ic&G Do. Ltd. Selected primers for detection of MAGE or GAGE genes for diagnosis of cancer and methods of use
KR20030032961A (ko) * 2000-06-06 2003-04-26 기린 비루 가부시키가이샤 내츄럴 킬러 ｔ 세포의 증폭 방법
WO2005014008A2 (en) * 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity
WO2011052638A1 (ja) 2009-10-28 2011-05-05 タカラバイオ株式会社 サイトカイン誘導キラー細胞の製造方法
AU2010347018A1 (en) * 2010-02-24 2012-09-20 Ingo Schmidt-Wolf Method for the generation of a CIK cell and NK cell population
CA2803391C (en) 2010-06-22 2021-11-09 Neogenix Oncology, Inc. Npc1 antibodies that bind a muc5ac epitope
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
BR112014008849A2 (pt) 2011-10-20 2017-09-12 Us Health receptores quiméricos de antígeno anti-cd22
US20150225697A1 (en) 2012-08-13 2015-08-13 Anthrogenesis Corporation Natural killer cells and uses thereof
DK2893004T3 (en) 2012-09-04 2019-02-04 Cellectis MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF
US20150329640A1 (en) 2012-12-20 2015-11-19 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
CN104017770B (zh) * 2014-06-23 2015-04-29 山东赛乐中德生物科技有限公司 一种利用糖脂制备cik细胞的方法
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN106434552B (zh) * 2015-08-13 2022-04-29 清华大学 新型nkt样细胞亚群及其治疗肿瘤的用途
CN105176927B (zh) * 2015-10-15 2019-01-18 丛秀丽 一种细胞毒性增强的高效靶向杀伤nk/cik细胞的制备方法
CN106566807A (zh) * 2016-10-21 2017-04-19 闾军 一种浓度梯度rhIL‑2依赖的iNKT细胞扩增方法及其应用
CN106434556B (zh) * 2016-11-22 2019-10-11 上海新长安生物科技有限公司 一种体外诱导扩增i型nkt细胞的方法
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
CN114258305A (zh) * 2019-08-21 2022-03-29 阿克索治疗公司 Iii型nkt细胞及相关组合物和方法
CN111172110B (zh) * 2019-12-20 2022-04-22 中科细胞科技(广州)有限公司 一种脐带血cik细胞的培养方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170029777A1 (en) 2014-01-27 2017-02-02 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof

Also Published As

Publication number Publication date
US20220347218A1 (en) 2022-11-03
KR20210028675A (ko) 2021-03-12
JP7190022B2 (ja) 2022-12-14
CA3105601C (en) 2024-01-16
JP2023012503A (ja) 2023-01-25
IL279924B1 (en) 2025-04-01
JP7664207B2 (ja) 2025-04-17
CN112424343B (zh) 2024-10-22
IL279924A (en) 2021-03-01
AU2024200673A1 (en) 2024-03-07
KR20230133942A (ko) 2023-09-19
IL319500A (en) 2025-05-01
EP3820994A1 (en) 2021-05-19
CN119372142A (zh) 2025-01-28
US11931382B2 (en) 2024-03-19
KR102778139B1 (ko) 2025-03-10
IL279924B2 (en) 2025-08-01
AU2019300782A1 (en) 2021-01-14
AU2019300782B2 (en) 2023-12-21
KR102577954B1 (ko) 2023-09-14
JP2025015816A (ja) 2025-01-30
JP2021530224A (ja) 2021-11-11
CA3105601A1 (en) 2020-01-16
US20240180967A1 (en) 2024-06-06
KR20240154707A (ko) 2024-10-25
CN112424343A (zh) 2021-02-26
WO2020014029A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
KR102721222B1 (ko) 제대혈로부터 cik nkt 세포의 생성
RU2671897C2 (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
JP6899333B2 (ja) 汎用キラーｔ細胞
DE102018108612A1 (de) Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
Wei et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma
KR101299299B1 (ko) 암면역 요법용 세포의 제조방법
Valipour et al. Cord blood stem cell derived CD16+ NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody
JP3904374B2 (ja) キラー活性を増強したリンパ球
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
US11351196B2 (en) Generating CIK NKT cells from cord blood
Asl et al. Intra-lesion injection of activated Natural Killer (NK) cells in recurrent Malignant brain tumors
Sánchez et al. Beyond CAR-T cells: Natural killer cells immunotherapy
CN101346463B (zh) 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法
RU2462511C2 (ru) Способ пролиферации клеток lak
CN110997003A (zh) 用nk-92细胞治疗和抑制白血病
US20220016167A1 (en) T-Rapa Cells as Novel Effector Cell Type for Chimeric Antigen Receptor Therapy
Asl et al. The Safety and Feasibility of Intra Surgical Cavity or intra Cerebrospinal Fluid (CSF) Injection of Haploidentical Activated NK Cells in Patients with Recurrent Glioblastoma Multiforme and Brain Tumors
CN117120596A (zh) 高效的m-cenk细胞和方法
HK40018395A (en) Treating and inhibiting leukemia with nk-92 cells
Wang et al. Research Article Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000